LifeMD, Inc. (NASDAQ:LFMD) Given Average Rating of "Buy" by Brokerages

LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) has been given a consensus rating of "Buy" by the six brokerages that are currently covering the firm, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $12.00.

Several equities research analysts have commented on LFMD shares. KeyCorp lowered their price objective on LifeMD from $12.00 to $10.00 and set an "overweight" rating on the stock in a research report on Thursday, July 11th. Cantor Fitzgerald reissued an "overweight" rating and set a $15.00 price target on shares of LifeMD in a report on Friday, September 20th. Finally, B. Riley initiated coverage on shares of LifeMD in a report on Friday, August 23rd. They issued a "buy" rating and a $11.00 price objective for the company.

LifeMD Stock Performance

Shares of LFMD stock traded up $0.24 during trading hours on Friday, hitting $4.32. The company's stock had a trading volume of 407,150 shares, compared to its average volume of 734,037. The company has a current ratio of 0.87, a quick ratio of 0.83 and a debt-to-equity ratio of 10.83. The company has a 50 day moving average of $4.85 and a 200 day moving average of $6.73. LifeMD has a 12-month low of $3.99 and a 12-month high of $12.88. The stock has a market cap of $186.06 million, a PE ratio of -6.17 and a beta of 1.18.

LifeMD (NASDAQ:LFMD - Get Free Report) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.06). The business had revenue of $50.66 million during the quarter, compared to the consensus estimate of $48.47 million. During the same quarter in the prior year, the company earned ($0.23) earnings per share. On average, sell-side analysts forecast that LifeMD will post -0.49 EPS for the current fiscal year.

Institutional Trading of LifeMD

Several institutional investors have recently modified their holdings of LFMD. Hussman Strategic Advisors Inc. acquired a new stake in shares of LifeMD in the first quarter worth approximately $432,000. Thompson Davis & CO. Inc. boosted its stake in LifeMD by 182.8% during the 1st quarter. Thompson Davis & CO. Inc. now owns 40,000 shares of the company's stock worth $411,000 after purchasing an additional 25,855 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in shares of LifeMD by 251.0% during the first quarter. Russell Investments Group Ltd. now owns 64,927 shares of the company's stock worth $667,000 after buying an additional 46,428 shares in the last quarter. Blair William & Co. IL acquired a new stake in shares of LifeMD in the first quarter valued at about $642,000. Finally, Vanguard Group Inc. lifted its stake in shares of LifeMD by 12.5% in the first quarter. Vanguard Group Inc. now owns 1,155,193 shares of the company's stock worth $11,875,000 after buying an additional 128,701 shares in the last quarter. Institutional investors and hedge funds own 35.52% of the company's stock.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.